- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001105
The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV
A Phase I Clinical Trial to Study the Toxicity, Pharmacokinetics, and Efficacy of Human Monoclonal Antibody, F105, for Treating Human Immunodeficiency Virus Infection.
To determine the safety and pharmacokinetics of F105 human monoclonal antibody both following a single dose and during intermittent administration in HIV-infected patients. To determine specific dose concentrations sufficient to achieve efficacy and avoid toxicity. To determine the effect of F105 on virologic, immunologic, and serologic parameters.
Early in the course of HIV infection, the primary humoral immune response appears to be highly strain specific and to be directed at a hypervariable portion of the viral gp120. The F105 human monoclonal antibody reacts with the CD4 binding region of gp120 and has been shown to neutralize the IIIB, SF2, and MN strains of HIV at concentrations readily achievable in humans.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Early in the course of HIV infection, the primary humoral immune response appears to be highly strain specific and to be directed at a hypervariable portion of the viral gp120. The F105 human monoclonal antibody reacts with the CD4 binding region of gp120 and has been shown to neutralize the IIIB, SF2, and MN strains of HIV at concentrations readily achievable in humans.
In Part A, three cohorts of four patients each receive a single intravenous (IV) injection of F105 human monoclonal antibody at 1 of 3 doses. The IV catheter will remain in the patient's arm for 12 hours after injection for subsequent drawing of blood samples. The third group (highest dose) will be studied only after the first two groups are analyzed for pharmacokinetics. No more than two patients are enrolled per week. Patients on Part A undergo follow-up three to four times within the first week after injection and weekly thereafter for 7 weeks. Pharmacokinetic and toxicity data generated from Part A will be used to select two dose levels for intermittent administration in Part B. In this part, cohorts of four to six patients receive one of two doses of F105 for 8-12 weeks.
Per 9/30/94 amendment, eight patients receive one dose of F105 every 21 days for four doses (dose determined from analysis of Part A data).
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Med. Ctr., ACTG CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
PART B ONLY. Allowed:
- Concomitant AZT or other antiretroviral drugs if patient is on a stable dose of such therapy within 3 months prior to study entry.
Patients must have:
- Documented HIV-1 infection.
- CD4 count 200 - 500 cells/mm3 (Part A) or <= 400 cells/mm3 (Part B, per amendment).
- No diagnosis of AIDS (Part A only, per amendment).
- Life expectancy of at least 6 months.
Part B patients only (per amendment):
- Primary (viral) isolates sensitive to F105 antibody using the yield reduction assay currently under development by ACTG, determined within 15-90 days prior to study entry.
- Plasma viremia by qualitative plasma culture.
- NO active opportunistic infection within 6 weeks prior to drawing of first isolate.
- NO AIDS-related malignancy other than minimal Kaposi's sarcoma.
Prior Medication:
Allowed:
- Prior AZT or other nucleoside antiviral agents.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Evidence of active renal disease as manifested by sediment containing red or white cell casts.
Concurrent Treatment:
Excluded:
- Red cell transfusions administered to maintain hemoglobin at acceptable level or alleviate symptoms of anemia.
Prior Medication:
Excluded within 6 weeks prior to study entry:
- Intravenous gamma globulin.
- Chemotherapy.
- Corticosteroids.
- Other experimental therapy.
EXCLUDED IN ALL PATIENTS:
- Immunosuppressive treatments, cytokine therapy, or biologic response modifiers not included in this study, including interferons or adjuvant treatment for chronic and severe fungal infections such as cryptococcal meningitis.
- Intravenous gamma globulin.
- Chemotherapy.
- Corticosteroids.
- Other experimental therapy.
- G-CSF, GM-CSF, or erythropoietin.
EXCLUDED IN PART A ONLY:
- Drugs known to enhance or block metabolism of other drugs.
EXCLUDED IN PART B ONLY:
- AZT or other antiretroviral drugs IF INITIATED during or within 1 month after completion of study.
Active alcohol or drug abuse that may compromise ability to comply with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Investigators
- Study Chair: Samore MH
Publications and helpful links
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG 232
- 11209 (Registry Identifier: DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on F105 Monoclonal Antibody (Human)
-
FibroGenCompletedIdiopathic Pulmonary FibrosisUnited States
-
Jiangsu T-Mab Biopharma Co.,LtdUnknown
-
Jiangsu T-Mab Biopharma Co.,LtdUnknown
-
Jiangsu T-Mab Biopharma Co.,LtdUnknown
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingUterine Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingLymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung CancerChina
-
Shanghai HyaMab Biotech Co.,Ltd.CompletedLocally Advanced/Metastatic Solid TumorsChina
-
Innate PharmaCompleted
-
Guangzhou Gloria Biosciences Co., Ltd.CompletedAdvanced Solid TumorsChina
-
BiocadCompleted